Baseline patient features for CEA and CAS after PSM
| Variables | Total (n = 152) | CAS (n = 76) | CEA (n = 76) | P value |
|---|---|---|---|---|
| Age, mean ± SD | 69.80 ± 11.35 | 70.14 ± 11.43 | 69.46 ± 11.27 | 0.383 |
| Male gender | 121 (80%) | 60 (79%) | 61 (80%) | 0.972 |
| Qualifying events | ||||
| Amaurosis fugax | 19 (13%) | 10 (13%) | 9 (12%) | 0.854 |
| TIA | 80 (53%) | 39 (51%) | 41 (54%) | 0.795 |
| Stroke | 12 (8%) | 5 (7%) | 7 (9%) | 0.855 |
| Asymptomatic | 46 (30%) | 22(29%) | 24 (32%) | 0.598 |
| Diabetes mellitus | 70 (46%) | 36 (47%) | 34 (45%) | 0.927 |
| Hypertension | 105 (69%) | 54 (71%) | 51 (67%) | 0.759 |
| Smoker | 107 (70%) | 52 (68%) | 55 (72%) | 0.095 |
| CAD | 89 (59%) | 47 (62%) | 42 (55%) | 0.067 |
| Previous MI | 49 (32%) | 27 (36%) | 22 (29%) | 0.079 |
| Previous CABG | 19 (13%) | 10 (13%) | 9 (12%) | 0.912 |
| Previous PTCA | 82 (54%) | 42 (55%) | 40 (53%) | 0.897 |
| Atrial fibrillation | 25 (16%) | 13 (17%) | 12 (16%) | 0.983 |
| PAD | 21 (14%) | 12 (16%) | 9 (12%) | 0.498 |
| COPD | 21 (14%) | 13(17%) | 8 (11%) | 0.068 |
| HDL, mean ± SD (mg/dL) | 37.97 ± 7.21 | 37.49 ± 6.57 | 38.45 ± 7.84 | 0.278 |
| LDL, mean ± SD (mg/dL) | 122.86 ± 26.31 | 121.46 ± 27.19 | 124.26 ± 25.43 | 0.629 |
| Triglycerides, mean ± SD | 209.67 ± 85.30 | 208.86 ± 68.24 | 210.47 ± 102.36 | 0.462 |
| Creatinine, mean ± SD (mg/dL) | 1.10 ± 0.58 | 1.09 ± 0.54 | 1.11 ± 0.62 | 0.241 |
| Glucose, mean ± SD (mg/dL) | 142.27 ± 63.46 | 140.86 ± 54.48 | 143.67 ± 72.44 | 0.428 |
| Preprocedural medication | ||||
| Aspirin | 137 (90%) | 67 (88%) | 70 (92%) | 0.786 |
| Clopidogrel | 102 (67%) | 53 (70%) | 49 (65%) | 0.617 |
| Antihypertensive | 92 (61%) | 48 (63%) | 44 (58%) | 0.083 |
| Statin | 152 (100%) | 76 (100%) | 76(100%) | 0.988 |